Abstract
A series of bis-arylurea and bis-arylamide derivatives based on 1H-benzo[d]imidazole moiety were designed, synthesized and evaluated as DFG-out B-RafV600E/VEGFR2 dual inhibitors. Compound 4a as the most potent compound displayed potential dual kinase inhibitory activities against B-RafV600E and VEGFR2 with IC50 values of 57.8 nM and 0.48 μM, as well as effective cellular antiproliferative potencies against A375 and HUVEC with IC50 values of 3.62 µM and 12.46 µM. 4a was also progressed to in vivo profiling, which exhibited similarly equivalent tumor growth inhibition (T/C = 17.99%) in human melanoma A375 (B-RafV600E) xenograft model by contrast to Sorafenib (T/C = 16.49%) without body weight loss.
Keywords: Antitumor, B-RafV600E, DFG-out type, dual inhibitors, 1H-benzo[d]imidazole moiety, VEGFR2.
Letters in Drug Design & Discovery
Title:Design, Synthesis and Antitumor Activities of Bis-arylureas and Bis-arylamides Based on1H-benzo[d]imidazole Moiety as Novel BRafV600E/VEGFR2 Dual inhibitors
Volume: 11 Issue: 9
Author(s): Weimin Yang, Yadong Chen, Yanmin Zhang, Sanzhi Tang, Hongli Chen, Weifang Tang and Tao Lu
Affiliation:
Keywords: Antitumor, B-RafV600E, DFG-out type, dual inhibitors, 1H-benzo[d]imidazole moiety, VEGFR2.
Abstract: A series of bis-arylurea and bis-arylamide derivatives based on 1H-benzo[d]imidazole moiety were designed, synthesized and evaluated as DFG-out B-RafV600E/VEGFR2 dual inhibitors. Compound 4a as the most potent compound displayed potential dual kinase inhibitory activities against B-RafV600E and VEGFR2 with IC50 values of 57.8 nM and 0.48 μM, as well as effective cellular antiproliferative potencies against A375 and HUVEC with IC50 values of 3.62 µM and 12.46 µM. 4a was also progressed to in vivo profiling, which exhibited similarly equivalent tumor growth inhibition (T/C = 17.99%) in human melanoma A375 (B-RafV600E) xenograft model by contrast to Sorafenib (T/C = 16.49%) without body weight loss.
Export Options
About this article
Cite this article as:
Yang Weimin, Chen Yadong, Zhang Yanmin, Tang Sanzhi, Chen Hongli, Tang Weifang and Lu Tao, Design, Synthesis and Antitumor Activities of Bis-arylureas and Bis-arylamides Based on1H-benzo[d]imidazole Moiety as Novel BRafV600E/VEGFR2 Dual inhibitors, Letters in Drug Design & Discovery 2014; 11 (9) . https://dx.doi.org/10.2174/1570180811666140724184806
DOI https://dx.doi.org/10.2174/1570180811666140724184806 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nutraceuticals in Psychiatric Practice
Recent Patents on CNS Drug Discovery (Discontinued) Evolution of Ipsilateral Head and Neck Radiotherapy
Current Cancer Therapy Reviews Steroid Receptor Ligands for Breast Cancer Targeting: An Insight into Their Potential Role As Pet Imaging Agents
Current Medicinal Chemistry The Long and Winding Road to Cancer Treatment: The Trail System
Current Pharmaceutical Design Theranostics of Metastatic Prostate Cancer Applying <sup>64</sup>Cu/<sup>18</sup>F/<sup>68</sup>Ga PSMA PET-CT and <sup>177</sup>Lu Radiopharmaceuticals
Current Radiopharmaceuticals MMP-9 Inhibitors in the Brain: Can Old Bullets Shoot New Targets?
Current Pharmaceutical Design Bacterial Toxins: Potential Weapons Against HIV Infection
Current Pharmaceutical Design Metallodrug Conjugates with Steroids and Selective Estrogen Receptor Modulators (SERM)
Current Medicinal Chemistry Targeted Alpha Therapy with 213Bi
Current Radiopharmaceuticals Regulation of miRNA Processing and miRNA Mediated Gene Repression in Cancer
MicroRNA Central Nervous System Disorders Associated to Immune Checkpoint Inhibitors
Current Cancer Therapy Reviews Techniques and Methods for In Vivo MRI Monitoring of Exogenous and Endogenous Neural Stem Cell-Mediated Brain Repair
Recent Patents on Regenerative Medicine Asymmetric 1,3-Dipolar Cycloadditons of Stabilized Azomethine Ylides with Nitroalkenes
Current Topics in Medicinal Chemistry Models to Study Atherosclerosis: A Mechanistic Insight
Current Vascular Pharmacology Alternative Splice Variants of Survivin as Potential Targets in Cancer
Current Drug Discovery Technologies Animal Mitochondria: Evolution, Function, and Disease
Current Molecular Medicine Resveratrol, a Phytochemical Inducer of Multiple Cell Death Pathways: Apoptosis, Autophagy and Mitotic Catastrophe
Current Medicinal Chemistry Serum Endocan, Neuron-Specific Enolase and Ischemia-Modified Albumin Levels in Newborns with Partial Blood Exchange Transfusion
Combinatorial Chemistry & High Throughput Screening Medicinal Plants Towards Modeling Skin Cancer
Current Drug Targets Meet Our Editorial Board Member
Current Medicinal Chemistry